Effect of Oral Antimicrobial Peptide R7I Against Epidemic Enteropathogenic Neisseria in Geese (Anser cygnoides orientalis)
2025
Shuo Jia | Junhan Gao | Jing Fu | Chongpeng Bi | Xiujing Dou | Anshan Shan
The emergence of antibiotic-resistant bacteria has resulted in a lack of available drugs that can be used to treat various diseases. Antimicrobial peptides (AMPs) are green and safe antibiotic alternatives. In 2022, an outbreak of an acute diarrheal disease caused by Gram-negative cocci named Neisseria occurred among domestic geese (Anser cygnoides orientalis) in Northeast China. In this study, we analyzed Neisseria S1, which caused diarrhea in geese, and determined whether AMP R7I designed in our laboratory can be used to treat Neisseria infection. This is the first report and isolation of enteropathogenic Neisseria, as well as the first report of Neisseria infection in Anser cygnoides orientalis. Peptide R7I has the capability to counteract Neisseria S1 infection both in vivo and in vitro. R7I induced the release of intracellular contents, leading to the death of Neisseria. Oral treatment of R7I modulated metabolic levels, antioxidant capacity, and immune responses and inhibited inflammation in Neisseria-infected geese. Furthermore, R7I significantly contributed to the recovery of intestinal homeostasis and regulated intestinal function via a signaling pathway related to metabolism in Neisseria infection. During our study of the mechanism of R7I against Neisseria infection, we preliminary found that R7I regulates lipid metabolism disorder and inflammation caused by Neisseria infection through the PPAR signaling pathway. In conclusion, R7I shows a strong ability against Neisseria infection, and it can be used as an oral antibiotic alternative in animal feed.
显示更多 [+] 显示较少 [-]